Shopping Cart 0
Cart Subtotal
USD 0

Reata Pharmaceuticals Inc (RETA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 750
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Summary

Reata Pharmaceuticals Inc (Reata) is a clinical-stage biopharmaceutical company that develops innovative medicines for the treatment of serious and life-threatening diseases. The company's clinical candidates include bardoxolone methyl and omaveloxolone, which target Nrf2, a transcription factor, for restoring mitochondrial function, reducing oxidative stress, and resolving inflammation. Reata is evaluating bardoxolone methyl in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH), Alport syndrome and other kidney diseases; and omaveloxolone in Friedreich's ataxia. The company works in partnership with academics, biotechnology and pharmaceutical companies to develop technologies, which disrupt the pathophysiological processes that lead to intractable diseases. Reata is headquartered in Irving, Texas, the US.

Reata Pharmaceuticals Inc (RETA)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Reata Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Reata Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Reata Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Reata Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Reata Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Reata Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 10

Partnerships 10

CNS Pharma Enters into Agreement with Reata Pharma 10

Licensing Agreements 11

Reata Pharma Enters into Licensing Agreement with University of Kansas 11

Equity Offering 12

Reata Pharma Raises USD248.4 Million in Public Offering of Shares 12

Reata Pharma Plans to Raise up to USD50 Million in Public Offering 14

Reata Pharma Raises USD115.8 Million in Public Offering of Shares 15

Reata Pharma Withdraws Public Offering of Shares for up to USD86.3 Million 17

Reata Pharma Raises USD69.6 Million in IPO of Shares 19

Reata Pharmaceuticals Inc-Key Competitors 21

Reata Pharmaceuticals Inc-Key Employees 22

Reata Pharmaceuticals Inc-Locations And Subsidiaries 23

Head Office 23

Other Locations & Subsidiaries 23

Recent Developments 24

Financial Announcements 24

Aug 08, 2018: Reata Pharmaceuticals announces second quarter 2018 financial results and an update on development programs 24

May 08, 2018: Reata Pharmaceuticals Announces First Quarter 2018 Financial Results and an Update on Development Programs 26

Mar 02, 2018: Reata Pharmaceuticals Announces Fourth Quarter and Full Year 2017 Financial and Operating Results 28

Nov 13, 2017: Reata Pharmaceuticals Announces Third Quarter 2017 Financial and Operating Results 30

Aug 14, 2017: Reata Pharmaceuticals Announces Second Quarter 2017 Financial and Operating Results 32

May 11, 2017: Reata pharmaceuticals announces first quarter 2017 financial and operating results 34

Mar 03, 2017: Reata Pharmaceuticals Announces Fourth Quarter and Full Year 2016 Financial and Operating Results 36

Corporate Communications 38

Mar 02, 2017: Reata Pharmaceuticals Announces the Retirement of Board Member Dennis Stone, M.D., and the Addition of New Board Member William D. McClellan, Jr. 38

Product Approvals 39

Jun 22, 2017: Reata Pharmaceuticals, Inc. Receives Orphan Drug Designation for Omaveloxolone for the Treatment of Friedreich's Ataxia 39

Clinical Trials 40

Jun 01, 2017: Reata Pharmaceuticals Announces Positive Data From Part One of Moxie Trial of Omaveloxolone for Friedreich's Ataxia 40

Appendix 43

Methodology 43

About GlobalData 43

Contact Us 43

Disclaimer 43


List Of Figure

List of Figures

Reata Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Reata Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Reata Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Reata Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Reata Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Reata Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Reata Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8


List Of Table

List of Tables

Reata Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Reata Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Reata Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Reata Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Reata Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 8

Reata Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

CNS Pharma Enters into Agreement with Reata Pharma 10

Reata Pharma Enters into Licensing Agreement with University of Kansas 11

Reata Pharma Raises USD248.4 Million in Public Offering of Shares 12

Reata Pharma Plans to Raise up to USD50 Million in Public Offering 14

Reata Pharma Raises USD115.8 Million in Public Offering of Shares 15

Reata Pharma Withdraws Public Offering of Shares for up to USD86.3 Million 17

Reata Pharma Raises USD69.6 Million in IPO of Shares 19

Reata Pharmaceuticals Inc, Key Competitors 21

Reata Pharmaceuticals Inc, Key Employees 22

Reata Pharmaceuticals Inc, Subsidiaries 23

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Reata Pharmaceuticals Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Summary

Reata Pharmaceuticals Inc (Reata) is a clinical-stage biopharmaceutical company that develops innovative medicines for the treatment of serious and life-threatening diseases. The company's clinical candidates include bardoxolone methyl and omaveloxolone, which target Nrf2, a transcription factor, for restoring mitochondrial function, reducing oxidative stress, and resolving inflammation. Reata is evaluating bardoxolone methyl in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH), Alport syndrome and other kidney diseases; and omaveloxolone in Friedreich's ataxia. The company works in partnership with academics, biotechnology and pharmaceutical companies to develop technologies, which disrupt the pathophysiological processes that lead to intractable diseases. Reata is headquartered in Irving, Texas, the US.

Reata Pharmaceuticals Inc (RETA)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Reata Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Reata Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Reata Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Reata Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Reata Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Reata Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 10

Partnerships 10

CNS Pharma Enters into Agreement with Reata Pharma 10

Licensing Agreements 11

Reata Pharma Enters into Licensing Agreement with University of Kansas 11

Equity Offering 12

Reata Pharma Raises USD248.4 Million in Public Offering of Shares 12

Reata Pharma Plans to Raise up to USD50 Million in Public Offering 14

Reata Pharma Raises USD115.8 Million in Public Offering of Shares 15

Reata Pharma Withdraws Public Offering of Shares for up to USD86.3 Million 17

Reata Pharma Raises USD69.6 Million in IPO of Shares 19

Reata Pharmaceuticals Inc-Key Competitors 21

Reata Pharmaceuticals Inc-Key Employees 22

Reata Pharmaceuticals Inc-Locations And Subsidiaries 23

Head Office 23

Other Locations & Subsidiaries 23

Recent Developments 24

Financial Announcements 24

Aug 08, 2018: Reata Pharmaceuticals announces second quarter 2018 financial results and an update on development programs 24

May 08, 2018: Reata Pharmaceuticals Announces First Quarter 2018 Financial Results and an Update on Development Programs 26

Mar 02, 2018: Reata Pharmaceuticals Announces Fourth Quarter and Full Year 2017 Financial and Operating Results 28

Nov 13, 2017: Reata Pharmaceuticals Announces Third Quarter 2017 Financial and Operating Results 30

Aug 14, 2017: Reata Pharmaceuticals Announces Second Quarter 2017 Financial and Operating Results 32

May 11, 2017: Reata pharmaceuticals announces first quarter 2017 financial and operating results 34

Mar 03, 2017: Reata Pharmaceuticals Announces Fourth Quarter and Full Year 2016 Financial and Operating Results 36

Corporate Communications 38

Mar 02, 2017: Reata Pharmaceuticals Announces the Retirement of Board Member Dennis Stone, M.D., and the Addition of New Board Member William D. McClellan, Jr. 38

Product Approvals 39

Jun 22, 2017: Reata Pharmaceuticals, Inc. Receives Orphan Drug Designation for Omaveloxolone for the Treatment of Friedreich's Ataxia 39

Clinical Trials 40

Jun 01, 2017: Reata Pharmaceuticals Announces Positive Data From Part One of Moxie Trial of Omaveloxolone for Friedreich's Ataxia 40

Appendix 43

Methodology 43

About GlobalData 43

Contact Us 43

Disclaimer 43


List Of Figure

List of Figures

Reata Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Reata Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Reata Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Reata Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Reata Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Reata Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Reata Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8


List Of Table

List of Tables

Reata Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Reata Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Reata Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Reata Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Reata Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 8

Reata Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

CNS Pharma Enters into Agreement with Reata Pharma 10

Reata Pharma Enters into Licensing Agreement with University of Kansas 11

Reata Pharma Raises USD248.4 Million in Public Offering of Shares 12

Reata Pharma Plans to Raise up to USD50 Million in Public Offering 14

Reata Pharma Raises USD115.8 Million in Public Offering of Shares 15

Reata Pharma Withdraws Public Offering of Shares for up to USD86.3 Million 17

Reata Pharma Raises USD69.6 Million in IPO of Shares 19

Reata Pharmaceuticals Inc, Key Competitors 21

Reata Pharmaceuticals Inc, Key Employees 22

Reata Pharmaceuticals Inc, Subsidiaries 23

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products

Reata Pharmaceuticals Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.